We analyzed genome-wide data in 19,779 cases (9,369 SCZ plus 10,410 BP) and 19,423 controls consisting of 1.1 million SNP dosages imputed using HapMap Phase 3 (21). Logistic regressions were performed controlling for sample and 13 quantitative indices of ancestry. We identified 219 SNPs in six genomic regions with p-values below the genome-wide significance threshold of 5 × 10−8 (Figure 1a, Table 2, Supplementary Table 3). The most significant SNP (rs1006737, p=5.5 × 10−13, OR=1.12) falls within the gene CACNA1C that was first found to be significant in BP (18, 39), subsequently in SCZ (17, 40) and recently for a best fit model in a 5 disease cross-disorder analysis (14). In our independent disease samples, we find similar odds ratios for both disorders (BP OR=1.127; SCZ OR=1.120). Of the other five genome-wide significant regions, the second most significant SNP is in the major histocompatibility complex (MHC) while the others are in or near the following genes TRANK1, MAD1L1, PIK3C2A, IFI44L. Four have been previously implicated in either SCZ (MHC, MAD1L1) (12, 19) or BP (TRANK1, IFI44L) (41) but the association
